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We have examined the repopulating ability of bone marrow and peripheral blood cells collected immediately and at intervals after treatment of donor mice with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCFJ. Using a competitive repopulation assay we showed that the repopulating ability of peripheral blood cells was highest immediately after cytokine treatment and declined to normal levels within 6 weeks of the termination of treatment with G-CSF and SCF. In contrast the repopulating a b i l i of bone marrow cells was low immediately after cytokine treatment and increased to levels that were IO-fold or more greater than marrow from untreated mice by 14 days after termination of treatment with G-CSF and SCF. This high level of repopulating activity declined to normal levels by 6 weeks after termination of treatment with G-CSF and SCF. The high level of repopulating ability was con-
HE in vivo administration of recombinant cytokines has
T had a great impact on the field of hematopoietic transplantation. Recombinant cytokines have been used to shorten the period of neutropenia after ablation of the recipient's bone Subsequent studies in both animal and human trials showed that in vivo administration of recombinant cytokines caused the mobilization of primitive hematopoietic progenitor cells (colony-forming unit granulocyte, erythroid, monocyte [CFU-GEM], CFU-granulocyte-macrophage [GM] , burst-forming unit-erythroid [BFU-E]) into the peripheral blood. Later it was shown that mobilized peripheral blood cells contained pluripotent hematopoietic stem cells (PHSC) that could repopulate the hematopoietic system of irradiated recipients." Recent reports have shown that cytokine-mobilized peripheral blood cells alone can be used for autologous bone marrow transplantation in human^.^, ^ We and others have studied the mobilization of hematopoietic progenitors and PHSC using granulocyte colonystimulating factor (G-CSF) and Stem Cell Factor (SCF). Either cytokine can mobilize PHSC into the peripheral blood as a single factor.'-'' Molineux et a17 have shown that following G-CSF treatment, irradiated mice could be repopulated with less than 50 yL of peripheral blood. We have shown that in mice treated with SCF, the repopulating ability of the peripheral blood and spleen is increased 10-and 5-fold, respectively. There was a corresponding decrease in the competitive repopulating ability of 2.4-fold.' Similar results were obtained by Fleming et all' who showed that cells with a PHSC phenotype (Thy-1.1'" lin-Sca-1 +) were mobilized into the peripheral blood and spleen. These cells were capable of radioprotection and long-term repopulation. Again, after SCF treatment the radioprotective ability of the bone marrow was decreased by more than twofold."
When G-CSF and SCF are used together, the effects are more dramatic. Briddell et all' and Molineux et allz have shown that administration of the combination of G-CSF and SCF to mice mobilized more CFU-GEM, CFU-GM, and BFU-E into the peripheral blood than either cytokine alone. We have shown that the administration of G-CSF and SCF firmed by injecting cells from G-CSF-and SCF-treated donors into unconditioned recipients. Peripheral blood cells collected immediately after treatment with G-CSF and SCF engrafted into unconditioned mice sevenfold better than an equivalent number of bone marrow cells from untreated mice. Likewise, bone marrow cells collected 14 days after treatment of the donor animal with G-CSF and SCF engrafted at 10-fold higher levels than an equivalent number of bone marrow cellsfrom untreated mice. We conclude that the treatment of donor mice with G-CSF and SCF causes a transient increase in the repopulating ability of peripheral blood and later of bone marrow. These observations may have applications to clinical hematopoietic stem cell transplantation. This is a US government work. There are no restrictions on its use.
to splenectomized mice increased the average number of PHSC in the peripheral blood more than 200-fold, whereas the average number of PHSC in the marrow decreased 4-fold.I3 Yan et all4 have shown that peripheral blood PHSC were capable of repopulating secondary recipients, establishing that they have significant self-renewal potential. Recent trials in humans have shown that cancer patients treated with G-CSF and SCF mobilized greater number of primitive progenitor cells into the peripheral blood than treatment with either cytokine alone. In addition, cotransplantation of peripheral blood progenitor cells mobilized by G-CSF and SCF decreased the time to platelet recovery after autologous bone marrow tran~plant.~.'~ In large animal models, complete repopulation of recipient primates and dogs has been achieved with allogeneic peripheral blood cells mobilized by administration of either G-CSF or SCF to the donor animals.16-'* In this report we examined the long-term effects of the administration of G-CSF and SCF to mice. We studied the repopulating ability of both bone marrow and peripheral blood at intervals for a period of 6 weeks after the termination of cytokine treatment. We found that the repopulating ability of the bone marrow rapidly increases after cytokine administration is terminated, reaching a level 10-fold or more greater than normal in 14 days. The repopulating ability of the peripheral blood rapidly drops to normal levels during this same period. Bone marrow cells collected from mice 14 days after cytokine treatment were more than IO-fold more 90 BODINE, SEIDEL, AND ORLIC efficient at engrafting into nonablated mice than normal bone marrow cells.
MATERIALS AND METHODS
Mice. All mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and were housed under specific pathogen-free conditions. Young adult (6 to 8 weeks) female, C57BL/6J or HW80 mice were used as donors of peripheral blood or bone marrow in all experiments. Experiments involving splenectomized mice were initiated at least 14 days after splenectomy. Competitor marrow for the competitive repopulation assay was obtained from B6.C H-lb/ ByJ (HW80) mice that are congenic with C57BU6.l mice except for single allelic differences at the mouse 0-globin IOCUS.'~ Recipients for competitive repopulation assay experiments were genetically anemic WBB6Fl-W/W2' mice or lethally irradiated (1,000 Gy I3'Cs source; 400 rad/min) WBB6F1-+/+ mice. No significant differences were observed between irradiated or genetically anemic recipients in the competitive repopulation assay. Unconditioned recipients were HW80 mice that received either peripheral blood or bone marrow cells from C57BL/6 mice. In one experiment unconditioned CS7BL/ 6 mice were injected with bone marrow from untreated HW80 mice.
Recombinant human G-CSF and recombinant rat SCF complexed with polyethylene glycol (PEG-SCF) were supplied by Amgen Inc (Thousand Oaks CA). Endotoxin levels were shown to be less than 2 pg/,ug of protein. The G-CSF and SCF were supplied at a concentrations of 530 and 1.0 mg/mL, respectively and were stored at 4°C until use. We have previously shown that 5 days of treatment with G-CSF and SCF mobilized the maximum number of PHSC into the peripheral blood.13 G-CSF and SCF were combined at a concentration of 40 mg/mL G-CSF and 10 mglmL SCF in phosphate-buffered saline (PBS) containing 0.1 % bovine serum albumin for injection. Donor mice (average weight 20 g) were injected daily with 0.1 mL subcutaneously for a daily dose of 200 mgkgld of G-CSF and 50 mgkgld of PEG-SCF for S days. The cytokine injections were scheduled so that the bone marrow and/or peripheral blood could be collected on the same day and competed against the same population of competitor bone marrow cells.
Peripheral blood was collected from the retroorbital sinus into heparinized capillary tubes (Thomas Scientific, Swedesboro, NJ). The peripheral blood white blood cell (WBC) count and red cell count was determined on a Coulter ZM counter (Coulter Electronics, Hialeah, FL). Differential counts were determined by examination of blood smears from five different animals (at least 100 cells counted per animal) stained with Wright's Giemsa.
Peripheral blood was collected from the retroorbital sinus under sterile conditions using a Pasteur pipette and washed in heparinhaline. An average of 1 mL (of an estimated blood volume of 1.8 mL) per mouse was collected. Mononuclear cells were collected after centrifugation through lymphocyte separation medium (LSM; Oragon Teknika, Durham, NC) according to the manufacturer's instructions. Bone marrow cells were collected by flushing the contents of femurs (21-gauge needle) and tibias (25-gauge needle) into PBS containing 2% fetal calf serum (Hyclone, Logan, UT). Single cell suspensions were generated by passing the marrow through a 21-gauge needle. Cell counts were performed using a hemacytometer after lysis of the red blood cells in 2% acetic acid. These values were used to determine both the bone marrow cellularity and the number of cells transplanted into recipient mice.
The competitive repopulation assay was performed as described by Harrison.2' Peripheral blood mononuclear cells or bone marrow cells from cytokine-treated CS7BL/6 mice collected at various times after cytokine treatment were mixed with an identical number of bone marrow cells from untreated HW80 mice. The cell concentrations were adjusted such Growth factors.
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that each recipient mouse received 1 X 10' cells from each donor. These conditions have been shown to accurately reflect up to 10-fold differences in repopulating ability to the limits of experimental error (3% to 5%).'"' CS7BL/6 and HW80 mice are genetically distinguishable at both the protein and DNA levels because of polymorphisms in the @-globin gene. CS7BL/6 mice are homozygous for the single allele at the mouse P-globin locus. In CS7BL/6 mice the 0-globin genes are located on two 10-kb EcoRI fragments. HW80 mice are homozygous for the diffuse allele at the mouse 0-globin locus. In HW80 mice the P-globin genes are located on 7-and 14-kb EcoRI fragments." The ratio of b-single to b-diffuse hemoglobin in the red cells was determined by electrophoresis on cellulose acetate gels by the method of Whitney." Four months or more after transplantation, the animals were killed to determine the relative number of the pIlngle and pdlffuse alleles in DNA from the bone marrow and thymus. After digestion with EcoRI the DNA was analyzed by Southern blot using a 61 1-base pair BamHIIPst I fragment from 1VS2 of the mouse P I n r gene as a probe. CFU-GM, CFU-GEM, and BFU-E were grown in complete methyl cellulose medium from Stem Cell Technologies (Vancouver, BC, Canada) according to the manufacturer's instructions. The CFU-GM colonies were counted on day 7 after plating, and the BFU-E and CFU-GEM colonies were counted on day 12 to 14 after plating.
Progenitor analysis.

RESULTS
Hematology.
To initiate these studies, splenectomized mice were treated with a 5-day course of G-CSF and SCF (200 and 25 p g k g l d , respectively). As w e have shown prev i o u~l y , '~ splenectomized mice have a higher W B C count than normal mice. Treatment with G-CSF and SCF increases the WBC greater than 100,000 cells/pL (Table 1 ). This increase was accompanied by an increase in the relative number of myeloid cells in the circulation, decreasing the percentage of cells with lymphocyte morphology from approximately 80% in untreated animals to approximately 45% in the cytokine-treated mice (Table 1 ). Cytokine treatment was discontinued after 5 days. By 7 days after treatment, the WBC had dropped to subnormal levels. By 14 and 28 days after treatment, respectively, the WBC and differential count had returned to normal levels (Table 1 ). There were no changes in the W B C or differential count of mice examined 6 weeks after cytokine treatment.
As reported by others, treatment with the combination of G-CSF and SCF mobilized myeloid progenitor cells (CFU-GM, BFU-E, and CFU-GEM) into the peripheral This was accompanied by a decrease of approximately twofold in the frequency of these progenitors in the marrow of cytokine-treated mice ( P < .05; Table 2 ). The absolute number of the progenitor cells in the peripheral blood did not compensate for the decrease in progenitor numbers in the marrow because of the difference in the cellularity of these organs. The decrease in the number of bone marrow progenitor cells persisted for at least the first 14 days after cytokine treatment. Bone marrow cellularity was estimated from the number of cells flushed from the hind limbs (2 femurs and 2 tibias). Bone marrow cellularity was decreased immediately after cytokine treatment ( P > .05; Table 2 ), but retumed to normal levels 7 days after treatment and remained normal throughout 6 weeks of evaluation (Table 1) . Effects of cytokine treatment on the number and distribution of pluripotent hematopoietic stem cells. The competitive repopulation assay" was used to assay for the relative number of PHSC. Splenectomized C57BLJ6J mice were treated for 5 days with G-CSF and SCF. Peripheral blood and bone marrow cells were collected from these animals at different times after cytokine treatment and mixed with an equal number of bone marrow cells from congenic untreated HW80 mice. After 16 weeks the relative number of red cells derived from each of the donor strains was measured by quantifying the amount of single and diffuse hemoglobin in the peripheral blood. Likewise, the relative number of lymphoid and myeloid cells was measured by quantifying the relative intensity of the bands representing the EcoRI restriction fragment length polymorphisms at the &globin locus. '9 The relative repopulating ability is defined as the ratio of C57BU6J hemoglobin to the amount of HW80 hemoglobin.2L,22 After 5 days of treatment with the combination of G-CSF and SCF, the relative repopulating ability of the peripheral blood compared with untreated marrow was 2.5 and 6.7 in two independent experiments (P < .001; Fig 1, Tables   3 and 4) . The repopulating ability of peripheral blood collected 14 and 28 days after cytokine treatment decreased to levels that are similar to that of untreated bone marrow and further declined to normal levels by 42 days after cytokine treatment (Fig 1, Tables 3 and 4) .
The repopulating ability of bone marrow from splenectomized and normal mice was equivalent (Table 3 and Bodine et all3). After 5 days of treatment with the combination of G-CSF and SCF the repopulating ability of bone marrow had declined to 0.27 relative to untreated marrow (P < ,001; For Table 3 ). and was similar to that of untreated marrow at 42 days after cytokine treatment (Fig 2, Tables 3 and 4) .
In the first three experiments, bone marrow cells collected from untreated mice were competed against equal numbers of bone marrow cells collected 14 days after cytokine treatment. In these recipients nearly 100% of the erythrocytes were derived from the cells collected 14 days after cytokine treatment. Harrison has shown that when the ratio of the experimental hemoglobin to the competitor hemoglobin is greater than 9: 1 (or vice versa), the competitive repopulation assay does not accurately predict the proportion of repopulating ~e l l s . 2 '~~~ To measure the relative repopulating ability of these two populations more accurately, two additional competitive repopulation experiments were conducted. In these experiments lo7 untreated bone marrow cells were competed against either 1 X lo6 (10-fold fewer) or 2.5 X Table 3 ).
lo6 ('$-fold fewer) bone marrow cells collected from mice 14 days after cytokine treatment. The relative amount of hemoglobin derived from the cytokine-treated and competitor bone marrow was well within the 95% confidence interval" (57% and 68% hemoglobin derived from the cytokinetreated cells, respectively). After corrections for the dilution, it was calculated that the relative repopulating ability of the cells collected 14 days after cytokine treatment was 8.3 and 14.4, respectively, compared with untreated marrow (P < .001; Tables 3 and 4) . Similarly, bone marrow collected 28 days after cytokine treatment was diluted 2.5-fold relative to untreated cells. The results of this experiment confirmed the higher relative repopulating ability of cells collected 28 days after cytokine treatment (Tables 3 and 4) .
DNA was extracted from the bone marrow and thymus of representative animals from each experimental group, and Southern analysis was performed to determine the relative contributions of the competing cell populations on nucleated myeloid and lymphoid cells. Digestion of the DNA with the restriction enzyme EcoRI reveals a restriction fragment length polymorphism in the P-globin cluster between the C57BL/6 and HW80 strains (Fig 3 and Weaver et all9) . In all cases, the relative amounts of the C57BL/6 and HW80 alleles in marrow and thymus DNA was similar to the relative amounts of hemoglobin derived from the C57BW6 and HW80 donors (Fig 3, Table 3 ). These results confirm that the erythroid, myeloid, and lymphoid lineages of the recipient mice were repopulated equivalently.
Estimation of the number of repopulating units per mouse. Harrison" has shown that the relative amount of the two hemoglobins in the peripheral blood is related to the relative number of repopulating units transplanted into the recipient mouse. A repopulating unit is defined as the smallest unit capable of complete repopulation of the recipient mouse. Mathematical models predict that complete hematopoietic repopulation requires 1 X lo5 bone marrow cellsz5; therefore we estimate the frequency of repopulating units in untreated bone marrow is 1 per lo5 bone marrow cells. The relative repopulating ability of the experimental cell population (Table 4) multiplied by the cellularity of the bone marrow or peripheral blood and the frequency of repopulating units in bone marrow (1/105 cells) to estimate the absolute number of repopulating units per mouse (see legend Table 5 ). The number of peripheral blood cells was calculated from the WBC and differential counts, based on a blood volume of 1.8 mL per mouse.26 The most widely cited estimate of the bone marrow cellularity of untreated mice is that of Chervenick et alZ7 who calculated a number of 2.4 X 10' bone mmow cells per mouse. This number was adjusted on the basis of the bone marrow cellularity shown in Table 2 . Using these calculations, we previously showed that normal mice have approximately 3,000 repopulating units, with approximately 2,400 in the marrow, 550 in the spleen, and less than 10 in the peripheral blood?
Untreated splenectomized mice had fewer repopulating units relative to normal mice because of the removal of the spleen (Table 5 and Bodine et all3). Treatment of splenectomized mice for 5 days with G-CSF and SCF increased the absolute number of repopulating units per mouse, particularly in the peripheral blood (P < .OOl ; Table 5 ). The number of repopulating units in the peripheral blood rapidly declined during the first 14 to 28 days after cytokine treatment and returned to pretreatment levels by 42 days after cytokine treatment ( Table 5 ). The largest increase in the absolute number of repopulating units was seen in bone marrow collected from mice 14 days after treatment with G-CSF and SCF, with a total of over 23,000 repopulating units per mouse, nearly all of which reside in the bone marrow (P < .001; Table 5 ). The number of repopulating units had returned to pretreatment levels 42 days after treatment with G-CSF and SCF (Table 5) .
Engraftment of bone marrow cells into unconditioned recipients. Engraftment of PHSC into recipient animals does not require prior marrow ablative treatment, and several groups have shown that the engraftment of PHSC into unconditioned recipients is dose-dependent.28-" When small numbers of bone marrow cells (1 to 2 X lo6) are injected, they compete against 100-to 200-fold more endogenous PHSC, and their progeny are difficult to detect. When larger numbers of cells (5 X lo7) are injected, their progeny are readily detected in the peripheral blood of the We reasoned that if cytokine treatment increased the repopulating ability of cells collected 14 days after cytokine treatment 10-fold or more, that these cells should have a greater ability to engraft into unconditioned recipients. As a control, between 2 X lo7 and 5 X lo7 bone marrow cells from untreated C57BU6 donors were injected into HW80 recipients or vice versa. As predicted, the amount of donor hemoglobin in the peripheral blood was low, approximately 2.5% donor hemoglobin per lo7 cells injected ( when between 3.5 X 10" and 5 X IO" peripheral blood cells collected from C57BW6 donors treated for 5 days with the combination of G-CSF and SCF were injected, the amount of donor hemoglobin in the peripheral blood averaged 17.7% donor hemoglobidl0' cells injected (P < .001; Table 6 ).
The injection of 2 X lo6 to 4 X 10" bone marrow cells collected from mice 14 days after cytokine treatment generated the highest levels of engraftment, 34.1% donor hemoglobidl0' cells injected (P < .001; Table 6 ). confirming the increased repopulating ability of this cell population.
DISCUSSION
The studies we describe indicate that the combination of G-CSF and SCF causes an immediate mobilization of hematopoietic stem and progenitor cells into the peripheral blood and later an increase in the repopulating ability of the bone marrow. The transient increase in the repopulating ability we observed after cytokine treatment may be due to either an increase in the absolute number PHSC or an improvement in the ability of the PHSC engraft and/or repopulate the recipient. Either hypothesis is consistent with the data we collected, because the assays we used to measure repopulating ability cannot distinguish between these possibilities. The classical methods to estimate PHSC numbers are not applicable to this problem. The mathematical model developed by Harrison and Stone's uses the binomial equation to estimate the relative number of PHSC using data from competitive repopulation assays. However, this analysis assumes that all PHSC contribute equally to repopulation," which prevents its application to this problem. FACS analysis has been used to measure the number of cells expressing phenotypic markers associated with PHSC, for example, Sca-I, Thy-I, or c-kit.3'-3" This type of analysis cannot be used to determine if the absolute number of PHSC is increased in our studies because these markers are expressed on some hematopoietic progenitor cells in addition to
The mechanism by which treatment with G-CSF and SCF mobilizes stem and progenitor cells into the peripheral blood and the subsequent transient increase in marrow repopulating ability is unknown. We suspect that the action of G-CSF and SCF indirectly affect the hematopoietic microenvironment, creating conditions in which the activation or expansion of primitive hematopoietic cells can occur. Support for this hypothesis is provided by in vitro studies that show that many agents can induce bone marrow macrophages, and stromal cells secrete a variety of cytokines proposed to influence PHSC, including interleukin-6 (IL-6) and IL-3.'7-'9 pHSC."'.>4
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Mobilization of progenitor cells into the peripheral blood of patients can typically be achieved with 20 mg/kg/d of G-CSF. If humans have the same the transient expansion of repopulating ability after cytokine treatment that we observed in the mouse, the increased repopulating ability of bone marrow from cytokine-treated donors could be used to reduce the risk of clinical bone marrow transplantation. For this to become practical, studies in human patients treated with G-CSF and SCF will be needed to determine the optimal time to collect the donor bone marrow cells. Although direct assays for the repopulating ability of human PHSC have not been demonstrated,@ the LTC-IC assay may allow similar studies to be performed on samples of patient bone m a r r~w .~' The recovery of repopulating ability in the bone mmow of mice after cytokine treatment suggests that cytokine treatment before collection of mobilized hematopoietic progenitor cells poses no long-term risk to the donor, other than the transient decrease in repopulating ability of the bone marrow seen immediately after cytokine treatment.
The transient expansion of repopulating ability that we observed may also have applications in the area of retrovirus- All hemoglobin measurements were made 16 weeks after injection of donor cells. Within each group are mice from at least two independent experiments.
Abbreviations: CK, cytokine; BM, bone marrow; PB, peripheral blood. * P = .ooo. t P = .ooo. mediated gene transfer. Retrovirus integration requires DNA synthesis; however, the majority of PHSC are in the Go phase of the cell cycle.33 In most murine and large animal gene transfer protocols, 5-fluorouracil treatment of the donor is included before marrow harvest with the intent of collecting activated PHSC for exposure to Regardless of whether the increased repopulating ability of bone marrow harvested from mice 14 days after cytokine treatment is due to increased numbers of PHSC arising by cell division or to increased activation of PHSC, which causes PHSC to divide rapidly upon return to the recipient animal, bone marrow cells from cytokine-treated mice may prove to be an improved target for retrovirus-mediated gene transfer, a hypothesis that we are testing.
